Compare Amylx Pharmaceuticals Inc (AMLX) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Expensify Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $24.03 (market cap $2.64B), while Expensify Inc trades at $2.27 (market cap $209.73M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 12.6× Expensify Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Expensify Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | EXFY | |
|---|---|---|
Market Cap | $2.64B | $209.73M |
Sector | Health | Technology |
52-Week High | $24.19 | $2.69 |
52-Week Low | $7.82 | $0.75 |
Enterprise Value | $2.39B | $149.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Expensify (EXFY) trades at $2.4, down 2.83% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. However, it remains unprofitable on a net income basis, with a negative margin of -11.31% and a high P/E ratio of 258.82, indicating a premium valuation despite losses. Recent news highlights expansion into Europe and AI product enhancements.
The outlook is mixed; operational improvements and AI-driven growth offer upside, but persistent losses and high valuation pose risks. Analyst sentiment is balanced with a 44% buy rating. Investors should weigh the potential for margin expansion against the challenge of achieving sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
